Business Context and Reporting Period
This Form 6-K, dated February 25, 2019, reports summary financial information for Novartis AG's Alcon eye care business. The data covers the full fiscal year ended December 31, 2018, and is presented ahead of a shareholder vote on the proposed 100% spin-off of Alcon scheduled for February 28, 2019. The figures are "carve-out" financials derived from Novartis consolidated statements to depict Alcon as a standalone entity.
Key Financial Metrics (FY 2018)
| Metric ($ millions) | 2018 | 2017 | 2016 |
|---|---|---|---|
| Net sales to third parties | 7,149 | 6,785 | 6,589 |
| Core gross profit | 4,541 | 4,211 | 4,123 |
| Core gross profit margin | 63.5% | 62.1% | 62.6% |
| Core operating income | 1,212 | 1,086 | 1,128 |
| Core operating income margin | 17.0% | 16.0% | 17.1% |
| IFRS reported operating (loss)/income | (248) | (77) | 10 |
Note: The filing does not provide specific data on cash flow, debt, or liquidity for the Alcon carve-out. IFRS reported operating income differs significantly from core operating income due to the exclusion of amortization and impairment charges in the core metrics.
Material Changes vs. Prior Period
- Sales Growth: Net sales increased by 5% in USD and 5% in constant currency (CC) compared to 2017.
- Profitability: Core gross profit rose 8% (USD) and 8% (CC). Core operating income increased 12% (USD) and 12% (CC).
- Margins: Core gross profit margin improved to 63.5% from 62.1%. Core operating income margin expanded to 17.0% from 16.0%.
- IFRS Impact: Despite strong core performance, IFRS operating income turned negative at $(248) million in 2018, compared to $(77) million in 2017, primarily driven by significant amortization and impairment charges.
Guidance, Outlook, and Risks
Outlook and Transaction: The financial data supports the proposed spin-off of Alcon. Full carve-out financial statements for 2018 are expected to be included in a future update to Alcon's Form 20-F registration statement.
Risks and Contingencies: The filing includes extensive forward-looking statements and risk factors, including:
- Uncertainty regarding the completion of the spin-off, including shareholder and regulatory approvals.
- Potential failure to realize expected synergies or strategic benefits post-spin-off.
- Global healthcare cost containment, pricing pressures, and regulatory actions.
- Risks related to the separation process, including maintaining relationships with customers, suppliers, and key personnel.
- Legal proceedings, intellectual property disputes, and product liability litigation.
- Macroeconomic factors, including exchange rate fluctuations and geopolitical instability.
Investor Verification Checklist
- Verify the final terms and completion status of the Alcon spin-off following the February 28, 2019, shareholder vote.
- Review the upcoming Alcon Form 20-F for full carve-out financial statements, including cash flow, debt, and liquidity metrics not present in this summary.
- Assess the impact of the $(996) million amortization and $(376) million impairment charges on future standalone IFRS earnings.
- Monitor regulatory approvals required for the transaction in key global markets.
- Evaluate the allocation methodology used for Novartis corporate general and administration expenses assigned to Alcon.